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The contact activation (CAS) and kallikrein/kinin (KKS) systems regulate thrombosis risk 
in two ways. First, the CAS influences contact activation-induced factor XI activation 
and thrombin formation through the hemostatic cascade. Second, prekallikrein (PK) 
and bradykinin of the KKS regulate expression of three vessel wall G-protein-coupled 
receptors, the bradykinin B2 receptor (B2R), angiotensin receptor 2, and Mas to influ-
ence prostacyclin formation. The degree of intravascular prostacyclin formation inversely 
regulates intravascular thrombosis risk. A 1.5- to 2-fold increase in prostacyclin, as 
seen in PK deficiency, increases vessel wall Sirt1 and KLF4 to downregulate vessel wall 
tissue factor which alone is sufficient to lengthen induced thrombosis times. A twofold to 
threefold increase in prostacyclin, as seen the B2R-deficient mouse, delays thrombosis 
and produces a selective platelet function defect of reduced GPVI activation and platelet 
spreading. Regulation of CAS and KKS protein expression has a profound influence on 
thrombosis-generating mechanisms in the intravascular compartment.
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The contact activation system (CAS) is known to initiate thrombus formation in surface-activated 
blood coagulation of plasma by factor XII (FXII) autoactivation with subsequent activation of 
plasma prekallikrein (PK), amplification of FXII and PK activation by each other, and subsequent 
activation of factor XI initiating a cascade of proteolytic reactions leading to thrombin formation 
(Figure 1). Plasma high-molecular weight kininogen (HK) accelerates these reactions. In a rabbit 
model of extracorporeal membrane oxygenation (ECMO), a novel Fab 3F7 directed to FXIIa and 
betaFXIIa reduced fibrin formation on the membrane oxygenator to the same extent as heparin 
(1). These data indicate that activations of the CAS leading to thrombin formation are blocked by 
inhibitors to FXIIa. Also in mice, CAS inhibition results in improved survival of F12−/− mice in the 
surface-activated collagen-, epinephrine-, or long-chain polyP-induced pulmonary embolism mod-
els when compared to wild type (WT) (2–4). In humans, FXIIa inhibition is useful to prevent in vivo 
contact activation from sepsis from any cause, adult respiratory distress syndrome, and when human 
blood comes in contact with artificial surfaces of medical devices such as ECMO, cardiopulmonary 
bypass, left-ventricular assist devices, and indwelling intravenous catheters (5). HK-deficient mice 
(Kgn1−/−) are also protected from thrombosis, but the mechanism for thrombosis delay is less well 
characterized (6). They appear to be like F12−/− mice, since Kgn1−/− mice also have improved survival 
after long-chain polyP infusions (4).
FiGURe 1 | The contact activation and kallikrein/kinin systems (KKS) 
have two mechanisms, whereby they influence thrombosis risk in the 
intravascular compartment. First, through contact autoactivation of factor 
XII (XII) to factor XIIa (XIIa), plasma prekallikrein (PK) is activated to plasma 
kallikrein (Kal) that then reciprocally activates XII and amplifies each other’s 
activation. Formed XIIa activates factor XI to factor XIa (XIa) that leads to 
thrombin formation. This pathway occurs in sepsis, adult respiratory distress 
syndrome, and on mechanical surfaces of devices used in the medical 
practice. The second pathway for thrombosis risk reduction is through the 
interaction of the plasma KKS with the renin–angiotensin system (RAS). 
Formed Kal cleaves bradykinin (BK) from high-molecular weight kininogen 
(HK), and it binds to the constitutive bradykinin B2 receptor (B2R). It 
stimulates cells to produce prostacyclin and NO. BK is metabolized by 
angiotensin-converting enzyme (ACE) that also converts angiotensin I to 
angiotensin II (AngII). If the angiotensin receptor 2 (AT2R) has more copies 
than the angiotensin receptor I (not shown), it binds to stimulate prostacyclin 
and NO. Also, AngII is metabolized to angiotensin-(1–7) [Ang-(1–7)] to 
stimulate its receptor, Mas, and also to produce prostacyclin and NO. 
Through the production of prostacyclin, each of these receptors has potential 
to regulate vessel wall tissue factor and change thrombosis risk within the 
intravascular compartment.
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However, other gene-deleted animals of the plasma CAS and 
kallikrein/kinin system (KAS) do not behave like F12−/− mice 
on contact activation-induced thrombosis assay. Plasma PK 
(Klkb1−/−) and bradykinin B2 receptor knockout (Bdkrb2−/−) mice 
do not have increased survival in the collagen-,  epinephrine-, or 
long-chain polyp-induced pulmonary embolism models (5,  7). 
Klkb1−/− mice have reduced contact activation as indicated by 
delayed contact activation thrombin generation times, long 
aPTT, and reduced lung edema after collagen–epinephrine insult 
(7). However, this reduced contact activation is not enough to 
provide thrombosis protection. Another mechanism is involved 
in its thrombosis protection. This assessment is the basis of 
the present review. Deficiencies of proteins of the plasma KKS 
(PK, bradykinin B2 receptor) allow for a novel mechanism for 
thrombosis protection through regulation of vessel wall tissue 
factor (TF) (Figure 1). Characterization of this mechanism is the 
basis of this report. In this pathway, regulation of vessel wall TF 
is mediated by vascular G-protein-coupled receptors (GPCRs) 
of the KKS and renin–angiotensin system (RAS) and their 
 influence on prostacyclin.
CHARACTeRiZATiOn OF Klkb1−/− MiCe
Detailed mechanistic investigations on PK-deficient mice 
reveal a previously unappreciated thrombosis protection path-
way that modulates in vivo thrombosis risk through regulation 
of vessel wall TF expression. The mechanism for this pathway 
is not obvious but was discovered by following the data from 
research observations. When we realized that Klkb1−/− mice 
have expected reduced contact activation, but do not have 
protection on contact activation-induced thrombosis assays, 
other mechanisms were sought. We observed that Klkb1−/− 
mice have reduced bradykinin (BK) to about 50% of the level 
of normal and higher than Kgn1−/− mice that have none (6, 7). 
We had expected that the bradykinin B2 receptor (B2R) that is 
constitutively expressed would be increased in response to low 
BK. To our surprise, the B2R was decreased. The B2R is known 
to make heterodimeric complexes with the angiotensin receptor 
2 (AT2R) and the Mas receptor (Mas) (8, 9). Furthermore, the 
B2R, AT2R, and Mas, when stimulated, all produce prostacyclin 
and NO. Finally, we knew from previous studies that in the 
absence of the B2R, AT2R and Mas become overexpressed (see 
below) (10, 11).
Investigations next determined if the AT2R and/or Mas 
receptor levels are increased. We observe increased Mas recep-
tor mRNA and protein with reduced AT2R and angiotensin-
converting enzyme (ACE) mRNA and normal angiotensin-(1–7) 
[Ang-(1–7)] levels (Figure 2). We next determined that a Mas 
receptor antagonist, A-779, corrects the prolonged thrombosis 
time in Klkb1−/− mice (7). Studies subsequently document that 
plasma prostacyclin, as measured by its stable plasma breakdown 
product 6-keto-PGF1α, is elevated, and the Mas antagonist 
A-779 corrects it to normal and nimesulide, a cyclooxygenase 
2 inhibitor, shortens Klkb1−/− mice thrombosis times to normal 
(8). Even though Klkb1−/− mice have elevated prostacyclin, 
thrombosis delay is not due to decreased platelet function. 
Klkb1−/− mice have normal bleeding times and platelet function 
as determined by thrombin-, CRP-, or ADP-induced platelet 
activation. Klkb1−/− mice also have normal platelet spreading on 
a collagen or fibrinogen matrix. Therefore, other mechanisms 
were sought.
Klkb1−/− mice have reduced platelet adherence on the 
cremasteric mouse laser injury thrombosis model. Since they 
have normal platelet function, we asked if there were reduced 
vessel wall TF (8). Aortic and carotid artery TF mRNA, protein, 
activity, and expression were reduced. Furthermore, plasma 
of Klkb1−/− mice has normal TF-induced thrombin generation 
times when 5  pM rTF is used. However, when 0.5  pM TF is 
employed, plasma from Klkb1−/− mice has reduced TF-induced 
thrombin generation. Recent studies by Barbieri and coworkers 
show that COX2−/− mice have increased vessel wall TF medi-
ated by reduced prostacyclin, allowing for reduction of the 
vasculoprotective transcription factor Sirt1 (12). We determined 
if Klkb1−/− mice have increased sirtuin 1 (silent mating type 
FiGURe 2 | Model for vessel wall tissue factor regulation in prekallikrein deficiency. In the absence of plasma prekallikrein (PK), there is reduced bradykinin 
(BK) and the bradykinin B2 receptor (B2R). This result is also associated with reduced angiotensin-converting enzyme activity (ACE) and the angiotensin receptor 2 
(AT2R) with elevation of the G-protein-coupled receptor Mas with normal angiotensin-(1–7) [Ang-(1–7), its natural ligand]. Increased Mas receptor alone is associated 
with a 1.5- to 2-fold elevation of prostacyclin (PGI2) with increased vessel wall Sirt1 and KLF4 and reduced vessel wall tissue factor (TF). There is no platelet function 
defect in prekallikrein-deficient platelets. The delayed thrombosis in PK-deficient mice is due to reduced vessel wall TF alone.
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information regulation 2 homolog 1) (Sirt1) and Kruppel-like 
factor 4 (KLF4), another vasculoprotective transcription factor. 
Klkb1−/− mice have increased Sirt1 and KLF4 mRNA and protein 
and on immunofluorescence, increased antigen is observed in 
the smooth muscle layer and endothelium, respectively (7). Since 
Sirt1 is a histone deacetylase that binds p65 of NFκB and KLF4 
binds the p300 co-activator of NFκB, the lowering of vessel wall 
TF in Klkb1−/− mice is not surprising. What is surprising in these 
animals is the recognition that modulation of vessel wall TF 
alone in Klkb1−/− mice is sufficient to alter in  vivo thrombosis 
risk in mice. This finding was unexpected and indicates that the 
Mas–prostacyclin axis is a mechanism for thrombosis risk regu-
lation. A summary of this mechanism for thrombosis protection 
in Klkb1−/− mice is shown in Figure 2.
CHARACTeRiZATiOn OF Bdkrb2−/− MiCe
We next asked if the thromboprotection mechanism seen 
in Klkb1−/− mice is observed in any other animals? Previous 
investigations in our laboratory show that Bdkrb2−/− mice also 
have delayed times to arterial thrombosis (10, 11). Our inves-
tigations reveal that in the absence of the B2R, both the AT2R 
and Mas receptors are increased as determined by mRNA and 
protein in kidney and aorta of these animals. Unlike Klkb1−/− 
mice, Bdkrb2−/− mice have elevated plasma BK, angiotensin 
II (AngII), and Ang-(1–7) (10, 11) (Figure  3). Also, plasma 
PK and plasminogen activator inhibitor-1 are increased, and 
factor XI is decreased (10). Antagonists to the Mas receptor 
(A-779) or AT2R (PD123319) are able to correct the delay in 
thrombosis occlusion to normal and both antagonists together 
are not additive (11). Furthermore, unlike Klkb1−/− mice, 
Bdkrb2−/− mice have long bleeding times (10, 11). Their plasma 
6-keto-PGF1α levels (259 ± 42 pg/ml) are significantly higher 
than Klkb1−/− mice (129 ± 12 pg/ml) (p < 0.003) and normals 
(75 ± 10 pg/ml) (7, 11). Twofold higher 6-keto-PGF1α levels 
produce the long bleeding times and the selective platelet 
function defect in Bdkrb2−/− mice (11). Bdkrb2−/− mice have 
a selective GPVI activation defect to collagen-rich peptide 
and convulxin. They manifest reduced murine activated 
integrin expression using the JON/A antibody and P-selectin 
expression. They also have a spreading defect on collagen, 
fibrinogen, and GFOGER, a β1 integrin adhesive peptide (11). 
On the other hand, Bdkrb2−/− mice have normal thrombin- 
and ADP-induced platelet activation and fibrinogen binding, 
respectively. Finally, the cyclooxygenase inhibitor, nimesulide, 
shortens the bleeding time to normal and corrects the time to 
thrombosis in these animals. However, the platelet inhibition 
mechanism in Bdkrb2−/− mice is not complete story for their 
delayed thrombosis times.
Bdkrb2−/− mice also have elevated Sirt1 and KLF4 mRNA in 
their vessel wall. We suspect that these animals too have reduced 
TF in their vessel walls. In support of that assessment, a recent 
investigation shows that BK reduces vessel wall TF via cell activa-
tion and this translates into reduced thrombosis risk (13). A sum-
mary of this mechanism for thrombosis delay in Bdkrb2−/− mice 
is shown in Figure 3.
FiGURe 3 | Mechanisms for thrombosis delay in the bradykinin B2 receptor-deleted mice. In the absence of the bradykinin B2 receptor (B2R), there is 
increased plasma bradykinin (BK), its ACE breakdown product, BK-(1–5) (RPPGF). There is also increased ACE, angiotensin II (AngII), and angiotensin-(1–7) 
[Ang-(1–7)]. Elevated AngII and Ang-(1–7) bind to increased angiotensin receptor 2 (AT2R) and Mas to increase prostacyclin (PGI2) levels twofold to threefold above 
normal. This elevation in plasma PGI2 results in increased vessel wall Sirt1 and KLF4 with reduced TF and a selective platelet function defect. The selective platelet 
function defect is reduced GPVI activation with normal thrombin- and ADP-induced platelet activation and reduced spreading on collagen and adhesive 
glycoproteins through β1 integrin binding. The delayed thrombosis in B2R-deficient mice is reduced vessel wall tissue factor a selective platelet function defect of 
GPVI activation and spreading.
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FiGURe 4 | The prostacyclin axis-induced thrombosis protection. PK and B2R deficiency produces thrombosis protection through the prostacyclin axis. In 
the absence of PK or the B2R, there is increased prostacyclin production due to overexpression of the AT2R and/or Mas receptors to compensate for reduced or 
absent B2R. Prostacyclin induces a graded increase in thrombosis protection. First, at levels up to twofold increased, it effects the vessel wall reducing TF 
production. Second, at levels up to twofold to threefold increased, it downregulates vessel wall TF and induces a selective platelet function defect of reduced GPVI 
activation and spreading on collagen- and integrin-binding adhesive glycoproteins. Finally, at levels greater that threefold, prostacyclin produces the overall platelet 
anesthesia generally recognized with it.
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SUMMARY
In conclusion, we have uncovered in our detailed mechanistic 
studies on the Klkb1−/− and Bdkrb2−/− mice, a previously unap-
preciated thrombo-protective mechanism. BK through the 
B2R receptor, AngII through the AT2R, or Ang-(1–7) through 
Mas receptor has the ability to elevate prostacyclin in a graded 
fashion. Graded elevation of prostacyclin has a graded increase 
in thrombo protection. First, it stimulates expression of vasculo-
protective transcription factors Sirt1 and KLF4 to downregulate 
vessel wall TF when increased 1.5- to 2-fold (Figure 4). Second, 
higher elevations (twofold to threefold increases) result in a selec-
tive platelet GPVI activation and spreading defect (Figure  4). 
These higher levels of prostacyclin lengthen bleeding times. 
Finally, higher concentrations of prostacyclin provide a general 
platelet anesthesia and give increased risk to bleed. Modulating 
vessel wall TF only through these three GPCRs may provide a 
novel approach to reduce thrombosis risk without enhanced risk 
to bleed.
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